TL;DR
It is suggested that PAFAH1B3 and PSMG3 may serve as valuable biomarkers and potential therapeutic targets in bladder cancer, however, further investigations are needed to establish their biological function and clinical relevance.
Five hub genes, colony-stimulating factor 2, apolipoprotein E, FN1, COL1A1, and intercellular adhesion molecule 1 may be biologically relevant hub genes in PTC, while FN1 and COL1A1 may have prognostic value.
This study defines a cross-population gene signature driving TSCC through ECM remodeling and immune modulation, and validation of STC2 as a prognostic marker highlights its potential for clinical risk stratification.
This integrated computational and experimental study identifies AURKB, CDC20, KIF11, and TOP2A as key oncogenic drivers in osteosarcoma, with significant diagnostic, prognostic, and therapeutic implications.
The findings of the current study offer that FN1, DPP4, CD36, KIT, ITGA2 and hsa-miR-124-3p may be novel biosignatures and therapeutic targets for PTC.
A seven-gene immune-related prognostic signature that, combined with clinicopathological parameters, provides a robust tool for individualized survival prediction and may guide precision management in CRC patients is developed and validated.
Findings support hsa-miR-200a as a potential breast cancer-associated miRNA biomarker candidate and highlight the utility of integrative transcriptomic and exploratory clinical serum approaches for future precision diagnostics.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
